Papa previously served as chairman and CEO of Bausch Health Companies.
Beyeonics Surgical announced that Joseph C. Papa will serve as chairman of the board. He will also serve as a board member for sister company Beyeonics Vision.
In a press release, Beyeonics CEO Ron Schnieder said, “We are thrilled to welcome Mr. Papa to our Board. His visionary leadership and immense professional experience resonate deeply with our mission and business objectives. With Joe's expertise, we will further elevate our impact on the healthcare landscape and advance innovations by making lasting impacts on surgeons and their patients.”
Papa previously served as chairman and CEO of Bausch Health Companies, and has a long career of working with medical device and pharmaceutical companies.
"Joining Ron and the experienced team at Beyeonics is an exciting opportunity," Mr. Papa said in the same press release. "I look forward to our mutual journey, taking the company through its next growth phase and to continue advancing our technology to help physicians improve health care outcomes and efficiency. I have confidence in Beyeonics' value proposition, which holds the potential to significantly transform the fields of Ophthalmology and Neurosurgery."
(Oct. 4, 2023); Beyeonics; Surgical Reality Pioneer, Beyeonics, Unveils New Chairman of the Board; https://www.prnewswire.com/news-releases/surgical-reality-pioneer-beyeonics-unveils-new-chairman-of-the-board-301946853.html
PD-L1 IHC 22C3 pharmD approved to help identify patients who may be eligible to receive treatment with pembrolizumab (Keytruda) to treat gastric or gastroesophageal junction adenocarcinoma.